Replies to post #115115 on NanoViricides Inc. (NNVC)

[JG36]

NanoViricides as well as our affiliates have added significant strength in our staffing, with the R&D staff more than doubling to over 20 persons this year.

Well we knew Theracour had made some new hires. The good news: The work might eventually get done. That bad news: NNVC is paying 30% more for this new labor than a normal biotech would. That's a dangerous extra overhead for an early stage biotech that will be bleeding money for many more years. And all so Dr. Diwan can have his lifestyle before actually getting a useful product out the door. With it's cost + 30% agreement with NNVC, Theracour must be piling up cash, all at NNVC shareholders' expense.

We believe that we will be able to make as much as a few kilograms in a single batch in the new cGMP-capable facility. We have continued to work successfully towards large-scale production of this anti-Influenza drug candidate. The Scale-Up Laboratory in our new Shelton campus now has the necessary equipment for this scale up. During and after each step is completed at the large scale, we must maintain certain process controls, obtain relevant data, and thereafter characterize the resulting products by various methods. This is a tedious, laborious, and time-consuming process.

Ho hum. No date given. NNVC has believed they'll have large scale production eventually for years. The question is, when?

And, yeah, it's a no brainer that Ebolacide2 didn't work. NNVC already said so. That's why we're at 1 clam.

[Paulness]

Thanks looking good !!

[changes_iv]

The production of FluCide(TM) material, for the third and final phase of tox studies, continues...

...In addition, we continue to perform step-wise scale up of production to enable multi-kg batches of our injectable anti-Influenza drug candidate for IND-enabling “Tox Package” studies. These studies are estimated to require up to 2.5 kg of the drug substance. We plan on scaling up from the 200g scale to 500g scale and then to 1kg scale. We may be able to combine several batches at either the 500g scale or at the 1 kg scale, provided that they are sufficiently equivalent in the characterization studies, in order to prepare a single master batch for further Tox Package studies. In the meantime, we have already performed preliminary safety/toxicology studies in rats using 200g material produced in our older R&D facilities in West Haven, CT. These studies have demonstrated excellent safety of FluCide. Previously, we have performed preliminary safety studies in mice as well. Those studies demonstrated excellent safety of FluCide. This led to the calculation of a very large quantity for our ensuing “Tox Package” studies for this drug candidate.

June 1, 2015, 9:47 PM
FluCide

Phase I and II of tox successfully completed

Making material for last Phase in large animals
.
.
.
Had FluCide not turned out to be so incredibly safe, we would have been done with tox by now. Incredibly safe is not a bad thing at all!

Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
[e-mail]
www.nanoviricides.com
310-486-5677
"NNVC" on the New York Stock Exchange

==================================================

"I suppose" the "con blogger", "Pump Terminator", could soon be coming out of his closet to reiterate everything he has blogged about in the past plus an update of why he/she/they believe the risk has jumped from 80% to 99%. "I must confess", I feel pretty certain that the sociopath/white-collar criminal will not be outdoing himself this time and instead rely solely on minimum wage cons/alias/anonymous posters.

Recent “Bear” Attack
As many of you know, a malicious and possibly criminal attack on our common stock was carried out on February 11, 2014, through the publication of a false and misleading article on Seeking Alpha. The intent of the article was to dramatically drive down our stock price. The article resulted in a highly increased daily trading volume of eight million shares, approximately 20 times our daily average. The information we have gathered suggests that this was an organized attack using false and inaccurate information designed to benefit short sellers in the stock. We have reported this conduct to the regulatory authorities and have retained legal counsel to investigate both the website that hosted this article and the
anonymous blogger who authored it.

www.nanoviricides.com/2014-ceo-letter.pdf